Scarica l'app Stockscreener
19.05
2.21%
-0.43
Dopo l'orario di chiusura:
18.85
-0.20
-1.05%
Precedente Chiudi:
$19.48
Aprire:
$19.37
Volume 24 ore:
1.20M
Relative Volume:
0.64
Capitalizzazione di mercato:
$1.69B
Reddito:
$217.42M
Utile/perdita netta:
$-243.25M
Rapporto P/E:
-6.8153
EPS:
-2.7952
Flusso di cassa netto:
$-278.35M
1 W Prestazione:
-8.46%
1M Prestazione:
-12.85%
6M Prestazione:
-6.20%
1 anno Prestazione:
+92.04%
Intervallo 1D:
$18.64
$19.50
Intervallo di 1 settimana:
$18.64
$21.57
Portata 52W:
$9.49
$25.59
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Nome
Syndax Pharmaceuticals Inc
Settore
Industria
Telefono
781-419-1400
Indirizzo
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
19.05 | 1.82B | 217.42M | -243.25M | -278.35M | -2.7952 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-16 | Ripresa | H.C. Wainwright | Buy |
| 2025-09-10 | Ripresa | Stifel | Buy |
| 2025-09-04 | Ripresa | Guggenheim | Buy |
| 2025-08-05 | Reiterato | BTIG Research | Buy |
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-06-28 | Iniziato | Jefferies | Buy |
| 2024-01-31 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | Iniziato | Mizuho | Buy |
| 2023-10-25 | Iniziato | BofA Securities | Buy |
| 2023-10-11 | Iniziato | Goldman | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-11 | Iniziato | Guggenheim | Buy |
| 2023-04-17 | Ripresa | BTIG Research | Buy |
| 2023-01-31 | Iniziato | Stifel | Buy |
| 2023-01-03 | Iniziato | JP Morgan | Overweight |
| 2022-07-28 | Ripresa | B. Riley Securities | Buy |
| 2022-04-11 | Iniziato | H.C. Wainwright | Buy |
| 2022-02-15 | Iniziato | Goldman | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-05-25 | Iniziato | Citigroup | Buy |
| 2021-02-18 | Iniziato | B. Riley Securities | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | Downgrade | Citigroup | Buy → Neutral |
| 2020-05-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-13 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-01-04 | Iniziato | Robert W. Baird | Outperform |
| 2018-01-05 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | Iniziato | FBR & Co. | Outperform |
| 2017-03-02 | Iniziato | Instinet | Buy |
| 2016-10-07 | Iniziato | Guggenheim | Buy |
| 2016-03-28 | Iniziato | Citigroup | Buy |
| 2016-03-28 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-03-28 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Syndax Pharmaceuticals Inc Borsa (SNDX) Ultime notizie
Syndax Pharmaceuticals to Report Second Quarter 2026 Financial Results and Host Conference Call on August 4 - Quiver Quantitative
Syndax will give a cancer-therapy business update Aug. 4 - Stock Titan
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026 - GlobeNewswire
Syndax Pharmaceuticals, Inc. $SNDX is Eversept Partners LP's 6th Largest Position - MarketBeat
Syndax Pharmaceuticals Inc (SNDX) Cash Flow - TradingKey
Syndax Pharmaceuticals Inc (SNDX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Syndax Pharmaceuticals (SNDX) Projected to Announce Quarterly Earnings on Monday - MarketBeat
Orbimed Advisors LLC Invests $22.48 Million in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
SNDX|Syndax Pharmaceuticals Inc|Price:20.810|Chg%:-0.400 - TradingKey
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Syndax Pharmaceuticals Inc (SNDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Granahan Investment Management LLC Cuts Stock Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Price to sales forward of Syndax Pharmaceuticals Inc – SWB:1T3 - TradingView
Syndax Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:SNDX - TradingView
Syndax Pharmaceuticals, Inc. (SNDX) Investor Outlook: A Promising 83.88% Upside Potential - DirectorsTalk Interviews
Syndax Pharmaceuticals Inc. (SNDX) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Technical Reactions to SNDX Trends in Macro Strategies - Stock Traders Daily
Barclays Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $37 - Moomoo
Syndax Pharmaceuticals (SNDX) Receives a New Rating from a Top Analyst - The Globe and Mail
Syndax Pharmaceuticals (SNDX) FDA Announcement Summary - Quartr
Syndax Pharmaceuticals (SNDX) TD Cowen 46th Annual Health Care Conference Summary - Quartr
Syndax Pharmaceuticals Holds Steady Near Support at $22.8 After Modest GainExhaustion Gap - dars.gov.et
Syndax Pharmaceuticals Inc. (SNDX) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Syndax Pharmaceuticals (SNDX) Is Up 8.20% in One Week: What You Should Know - Yahoo! Finance Canada
Syndax Pharmaceuticals (SNDX) Could Be 40% Undervalued As Pipeline Updates Sharpen Growth Story - Sahm
SNDX Stock Price, Quote & Chart - ChartMill
Goldman Sachs Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Analysts Have Conflicting Sentiments on These Healthcare Companies: HCA Healthcare (HCA) and Syndax Pharmaceuticals (SNDX) - The Globe and Mail
TD Cowen Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating - Moomoo
SNDX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
Stifel Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $46 - Moomoo
Syndax Pharmaceuticals unveils new pipeline candidates - BioWorld News
Syndax Pharmaceuticals (NASDAQ:SNDX) Earns "Buy" Rating from HC Wainwright - MarketBeat
H.C. Wainwright reiterates Syndax Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Citi Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $57 - Moomoo
Syndax Showcases Late-Stage Pipeline, Expands R&D Strategy - TipRanks
SNDX6417984 Bond Coupon Profile — Rate & Payments - TradingView
Syndax Pharmaceuticals Inc to Host R&D Day Transcript - GuruFocus
SNDX6417984 Bond Profile — Key Metrics - TradingView
A Fresh Look At Syndax Pharmaceuticals (NASDAQ:SNDX) - Seeking Alpha
Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push - MarketBeat
Syndax Pharmaceuticals, Inc. (SNDX) Discusses Pipeline Expansion and Next Phase of Innovation for Lead TherapiesSlideshow (NASDAQ:SNDX) 2026-07-14 - Seeking Alpha
Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet - Yahoo! Finance Canada
SNDX: New pipeline assets and late-stage programs drive clinical and commercial growth through 2027 - TradingView
Syndax (NASDAQ: SNDX) details pipeline expansion and 2026-27 clinical catalysts - Stock Titan
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event - The Manila Times
Form 4 Syndax Pharmaceuticals For: 9 July By Investing.com - Investing.com Nigeria
Syndax CEO Michael Metzger sells $784,776 in company stock By Investing.com - Investing.com Nigeria
Syndax CEO Michael Metzger sells $784,776 in company stock - Investing.com
Syndax Pharmaceuticals Insider Sold Shares Worth $784,776, According to a Recent SEC Filing - Moomoo
Syndax (SNDX) CEO Metzger exercises options and sells 32,375 shares under 10b5-1 plan - Stock Titan
Syndax Pharmaceuticals Inc Azioni (SNDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Syndax Pharmaceuticals Inc Azioni (SNDX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Metzger Michael A | Chief Executive Officer |
Jul 08 '26 |
Sale |
24.24 |
32,375 |
784,776 |
484,843 |
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):